Global Neuromuscular Blockade Drugs Production, Demand and Key Producers, 2022-2028
Neuromuscular blocking agents or medications are the type of muscle relaxants that are widely used to prevent muscle contraction during surgery. They are structurally similar to acetylcholine and bring muscle relaxation by post-synaptic binding to acetylcholine receptors. Furthermore, when artificial ventilation is available, such agents should be used instead of anesthesia.
This report studies the global Neuromuscular Blockade Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Neuromuscular Blockade Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Neuromuscular Blockade Drugs that contribute to its increasing demand across many markets.
The global Neuromuscular Blockade Drugs market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Neuromuscular Blockade Drugs total production and demand, 2017-2028, (K Units)
Global Neuromuscular Blockade Drugs total production value, 2017-2028, (USD Million)
Global Neuromuscular Blockade Drugs production by region & country, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Neuromuscular Blockade Drugs consumption by region & country, CAGR, 2017-2028 & (K Units)
U.S. VS China: Neuromuscular Blockade Drugs domestic production, consumption, key domestic manufacturers and share
Global Neuromuscular Blockade Drugs production by manufacturer, production, price, value and market share 2017-2022, (USD Million) & (K Units)
Global Neuromuscular Blockade Drugs production by Type, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Neuromuscular Blockade Drugs production by Application production, value, CAGR, 2017-2028, (USD Million) & (K Units)
This reports profiles key players in the global Neuromuscular Blockade Drugs market based on the following parameters – headquarters, production locations, products portfolio, Neuromuscular Blockade Drugs revenue, sales, average price and gross margin, recent developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Neuromuscular Blockade Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Neuromuscular Blockade Drugs Market, By Region:
1. How big is the global Neuromuscular Blockade Drugs market?
2. What is the demand of the global Neuromuscular Blockade Drugs market?
3. What is the year over year growth of the global Neuromuscular Blockade Drugs market?
4. What is the production and production value of the global Neuromuscular Blockade Drugs market?
5. Who are the key producers in the global Neuromuscular Blockade Drugs market?
6. What are the growth factors driving the market demand?
This report studies the global Neuromuscular Blockade Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Neuromuscular Blockade Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Neuromuscular Blockade Drugs that contribute to its increasing demand across many markets.
The global Neuromuscular Blockade Drugs market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Neuromuscular Blockade Drugs total production and demand, 2017-2028, (K Units)
Global Neuromuscular Blockade Drugs total production value, 2017-2028, (USD Million)
Global Neuromuscular Blockade Drugs production by region & country, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Neuromuscular Blockade Drugs consumption by region & country, CAGR, 2017-2028 & (K Units)
U.S. VS China: Neuromuscular Blockade Drugs domestic production, consumption, key domestic manufacturers and share
Global Neuromuscular Blockade Drugs production by manufacturer, production, price, value and market share 2017-2022, (USD Million) & (K Units)
Global Neuromuscular Blockade Drugs production by Type, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Neuromuscular Blockade Drugs production by Application production, value, CAGR, 2017-2028, (USD Million) & (K Units)
This reports profiles key players in the global Neuromuscular Blockade Drugs market based on the following parameters – headquarters, production locations, products portfolio, Neuromuscular Blockade Drugs revenue, sales, average price and gross margin, recent developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Neuromuscular Blockade Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Neuromuscular Blockade Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Depolarizing
- Non-Depolarizing
- Hospitals
- Specialty Clinics
- Other
- F. Hoffmann-La Roche Ltd
- Mylan N.V
- Teva Pharmaceutical Industries Ltd
- Sanofi
- Pfizer Inc
- GSK plc
- Novartis AG
- AstraZeneca
- Johnson & Johnson Private Limited
- Sun Pharmaceutical Industries Ltd
- Merck & Co., Inc
- Lilly
- Amgen Inc
- Actelion Pharmaceuticals Ltd
- Endo International plc
- Intas Pharmaceuticals Ltd
1. How big is the global Neuromuscular Blockade Drugs market?
2. What is the demand of the global Neuromuscular Blockade Drugs market?
3. What is the year over year growth of the global Neuromuscular Blockade Drugs market?
4. What is the production and production value of the global Neuromuscular Blockade Drugs market?
5. Who are the key producers in the global Neuromuscular Blockade Drugs market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Neuromuscular Blockade Drugs Introduction
1.2 World Neuromuscular Blockade Drugs Supply & Forecast
1.2.1 World Neuromuscular Blockade Drugs Production Value (2017 & 2021 & 2028)
1.2.2 World Neuromuscular Blockade Drugs Production (2017-2028)
1.2.3 World Neuromuscular Blockade Drugs Pricing Trends (2017-2028)
1.3 World Neuromuscular Blockade Drugs Production by Region
1.3.1 World Neuromuscular Blockade Drugs Production Value by Region (2017-2028)
1.3.2 World Neuromuscular Blockade Drugs Production by Region (2017-2028)
1.3.3 World Neuromuscular Blockade Drugs Average Price by Region (2017-2028)
1.3.4 North America Neuromuscular Blockade Drugs Production (2017-2028)
1.3.5 Europe Neuromuscular Blockade Drugs Production (2017-2028)
1.3.6 China Neuromuscular Blockade Drugs Production (2017-2028)
1.3.7 Japan Neuromuscular Blockade Drugs Production (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Neuromuscular Blockade Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Neuromuscular Blockade Drugs Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Neuromuscular Blockade Drugs Demand (2017-2028)
2.2 World Neuromuscular Blockade Drugs Consumption by Region
2.2.1 World Neuromuscular Blockade Drugs Consumption by Region (2017-2022)
2.2.2 World Neuromuscular Blockade Drugs Consumption Forecast by Region (2023-2028)
2.3 United States Neuromuscular Blockade Drugs Consumption (2017-2028)
2.4 China Neuromuscular Blockade Drugs Consumption (2017-2028)
2.5 Europe Neuromuscular Blockade Drugs Consumption (2017-2028)
2.6 Japan Neuromuscular Blockade Drugs Consumption (2017-2028)
2.7 South Korea Neuromuscular Blockade Drugs Consumption (2017-2028)
2.8 ASEAN Neuromuscular Blockade Drugs Consumption (2017-2028)
2.9 India Neuromuscular Blockade Drugs Consumption (2017-2028)
3 WORLD NEUROMUSCULAR BLOCKADE DRUGS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Neuromuscular Blockade Drugs Production Value by Manufacturer (2017-2022)
3.2 World Neuromuscular Blockade Drugs Production by Manufacturer (2017-2022)
3.3 World Neuromuscular Blockade Drugs Average Price by Manufacturer (2017-2022)
3.4 Neuromuscular Blockade Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Neuromuscular Blockade Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Neuromuscular Blockade Drugs in 2021
3.5.3 Global Concentration Ratios (CR8) for Neuromuscular Blockade Drugs in 2021
3.6 Neuromuscular Blockade Drugs Market: Overall Company Footprint Analysis
3.6.1 Neuromuscular Blockade Drugs Market: Region Footprint
3.6.2 Neuromuscular Blockade Drugs Market: Company Product Type Footprint
3.6.3 Neuromuscular Blockade Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Neuromuscular Blockade Drugs Production Value Comparison
4.1.1 United States VS China: Neuromuscular Blockade Drugs Production Value Comparison (2017 & 2021 & 2028)
4.1.2 United States VS China: Neuromuscular Blockade Drugs Production Value Market Share Comparison (2017 & 2021 & 2028)
4.2 United States VS China: Neuromuscular Blockade Drugs Production Comparison
4.2.1 United States VS China: Neuromuscular Blockade Drugs Production Comparison (2017 & 2021 & 2028)
4.2.2 United States VS China: Neuromuscular Blockade Drugs Production Market Share Comparison (2017 & 2021 & 2028)
4.3 United States VS China: Neuromuscular Blockade Drugs Consumption Comparison
4.3.1 United States VS China: Neuromuscular Blockade Drugs Consumption Comparison (2017 & 2021 & 2028)
4.3.2 United States VS China: Neuromuscular Blockade Drugs Consumption Market Share Comparison (2017 & 2021 & 2028)
4.4 United States Neuromuscular Blockade Drugs Key Producers and Market Share, 2017-2022
4.4.1 Major Manufacturer of Neuromuscular Blockade Drugs in United States, Company Headquarters and Production Place (States, Country)
4.4.2 United States Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022)
4.4.3 United States Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022)
4.5 China Neuromuscular Blockade Drugs Key Producers and Market Share, 2017-2022
4.5.1 Major Manufacturer of Neuromuscular Blockade Drugs in China, Company Headquarters and Production Place (Province, Country)
4.5.2 China Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022)
4.5.3 China Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022)
4.6 Rest of World Neuromuscular Blockade Drugs Key Producers and Market Share, 2017-2022
4.6.1 Major Manufacturer of Neuromuscular Blockade Drugs in Rest of World, Company Headquarters and Production Place (State, Country)
4.6.2 Rest of World Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022)
4.6.3 Rest of World Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022)
5 MARKET ANALYSIS BY TYPE
5.1 World Neuromuscular Blockade Drugs Market Size Overview by Type: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Type
5.2.1 Depolarizing
5.2.2 Non-Depolarizing
5.3 Market Segment by Type
5.3.1 World Neuromuscular Blockade Drugs Production by Type (2017-2028)
5.3.2 World Neuromuscular Blockade Drugs Production Value by Type (2017-2028)
5.3.3 World Neuromuscular Blockade Drugs Average Price by Type (2017-2028)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Neuromuscular Blockade Drugs Market Size Overview by Application: 2017 VS 2021 VS 2028
6.2 Segment Introduction by Application
6.2.1 Hospitals
6.2.2 Specialty Clinics
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Neuromuscular Blockade Drugs Production by Application (2017-2028)
6.3.2 World Neuromuscular Blockade Drugs Production Value by Application (2017-2028)
6.3.3 World Neuromuscular Blockade Drugs Average Price by Application (2017-2028)
7 COMPANY PROFILES
7.1 F. Hoffmann-La Roche Ltd
7.1.1 F. Hoffmann-La Roche Ltd Details
7.1.2 F. Hoffmann-La Roche Ltd Major Business
7.1.3 F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Product and Services
7.1.4 F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
7.1.6 F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
7.2 Mylan N.V
7.2.1 Mylan N.V Details
7.2.2 Mylan N.V Major Business
7.2.3 Mylan N.V Neuromuscular Blockade Drugs Product and Services
7.2.4 Mylan N.V Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.2.5 Mylan N.V Recent Developments/Updates
7.2.6 Mylan N.V Competitive Strengths & Weaknesses
7.3 Teva Pharmaceutical Industries Ltd
7.3.1 Teva Pharmaceutical Industries Ltd Details
7.3.2 Teva Pharmaceutical Industries Ltd Major Business
7.3.3 Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product and Services
7.3.4 Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.3.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
7.3.6 Teva Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
7.4 Sanofi
7.4.1 Sanofi Details
7.4.2 Sanofi Major Business
7.4.3 Sanofi Neuromuscular Blockade Drugs Product and Services
7.4.4 Sanofi Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.4.5 Sanofi Recent Developments/Updates
7.4.6 Sanofi Competitive Strengths & Weaknesses
7.5 Pfizer Inc
7.5.1 Pfizer Inc Details
7.5.2 Pfizer Inc Major Business
7.5.3 Pfizer Inc Neuromuscular Blockade Drugs Product and Services
7.5.4 Pfizer Inc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.5.5 Pfizer Inc Recent Developments/Updates
7.5.6 Pfizer Inc Competitive Strengths & Weaknesses
7.6 GSK plc
7.6.1 GSK plc Details
7.6.2 GSK plc Major Business
7.6.3 GSK plc Neuromuscular Blockade Drugs Product and Services
7.6.4 GSK plc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.6.5 GSK plc Recent Developments/Updates
7.6.6 GSK plc Competitive Strengths & Weaknesses
7.7 Novartis AG
7.7.1 Novartis AG Details
7.7.2 Novartis AG Major Business
7.7.3 Novartis AG Neuromuscular Blockade Drugs Product and Services
7.7.4 Novartis AG Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.7.5 Novartis AG Recent Developments/Updates
7.7.6 Novartis AG Competitive Strengths & Weaknesses
7.8 AstraZeneca
7.8.1 AstraZeneca Details
7.8.2 AstraZeneca Major Business
7.8.3 AstraZeneca Neuromuscular Blockade Drugs Product and Services
7.8.4 AstraZeneca Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.8.5 AstraZeneca Recent Developments/Updates
7.8.6 AstraZeneca Competitive Strengths & Weaknesses
7.9 Johnson & Johnson Private Limited
7.9.1 Johnson & Johnson Private Limited Details
7.9.2 Johnson & Johnson Private Limited Major Business
7.9.3 Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Product and Services
7.9.4 Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.9.5 Johnson & Johnson Private Limited Recent Developments/Updates
7.9.6 Johnson & Johnson Private Limited Competitive Strengths & Weaknesses
7.10 Sun Pharmaceutical Industries Ltd
7.10.1 Sun Pharmaceutical Industries Ltd Details
7.10.2 Sun Pharmaceutical Industries Ltd Major Business
7.10.3 Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product and Services
7.10.4 Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.10.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
7.10.6 Sun Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
7.11 Merck & Co., Inc
7.11.1 Merck & Co., Inc Details
7.11.2 Merck & Co., Inc Major Business
7.11.3 Merck & Co., Inc Neuromuscular Blockade Drugs Product and Services
7.11.4 Merck & Co., Inc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.11.5 Merck & Co., Inc Recent Developments/Updates
7.11.6 Merck & Co., Inc Competitive Strengths & Weaknesses
7.12 Lilly
7.12.1 Lilly Details
7.12.2 Lilly Major Business
7.12.3 Lilly Neuromuscular Blockade Drugs Product and Services
7.12.4 Lilly Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.12.5 Lilly Recent Developments/Updates
7.12.6 Lilly Competitive Strengths & Weaknesses
7.13 Amgen Inc
7.13.1 Amgen Inc Details
7.13.2 Amgen Inc Major Business
7.13.3 Amgen Inc Neuromuscular Blockade Drugs Product and Services
7.13.4 Amgen Inc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.13.5 Amgen Inc Recent Developments/Updates
7.13.6 Amgen Inc Competitive Strengths & Weaknesses
7.14 Actelion Pharmaceuticals Ltd
7.14.1 Actelion Pharmaceuticals Ltd Details
7.14.2 Actelion Pharmaceuticals Ltd Major Business
7.14.3 Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product and Services
7.14.4 Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.14.5 Actelion Pharmaceuticals Ltd Recent Developments/Updates
7.14.6 Actelion Pharmaceuticals Ltd Competitive Strengths & Weaknesses
7.15 Endo International plc
7.15.1 Endo International plc Details
7.15.2 Endo International plc Major Business
7.15.3 Endo International plc Neuromuscular Blockade Drugs Product and Services
7.15.4 Endo International plc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.15.5 Endo International plc Recent Developments/Updates
7.15.6 Endo International plc Competitive Strengths & Weaknesses
7.16 Intas Pharmaceuticals Ltd
7.16.1 Intas Pharmaceuticals Ltd Details
7.16.2 Intas Pharmaceuticals Ltd Major Business
7.16.3 Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product and Services
7.16.4 Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.16.5 Intas Pharmaceuticals Ltd Recent Developments/Updates
7.16.6 Intas Pharmaceuticals Ltd Competitive Strengths & Weaknesses
8 RAW MATERIAL AND INDUSTRY CHAIN
8.1 Raw Material of Neuromuscular Blockade Drugs and Key Manufacturers
8.2 Neuromuscular Blockade Drugs Manufacturing Costs
8.3 Neuromuscular Blockade Drugs Production Process
8.4 Neuromuscular Blockade Drugs Industrial Chain
9 DISTRIBUTION CHANNEL ANALYSIS
9.1 Distribution Channel Breakdown for Neuromuscular Blockade Drugs Shipments (%): 2017-2028
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Neuromuscular Blockade Drugs Typical Distributors
9.3 Neuromuscular Blockade Drugs Typical Customers
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
1.1 Neuromuscular Blockade Drugs Introduction
1.2 World Neuromuscular Blockade Drugs Supply & Forecast
1.2.1 World Neuromuscular Blockade Drugs Production Value (2017 & 2021 & 2028)
1.2.2 World Neuromuscular Blockade Drugs Production (2017-2028)
1.2.3 World Neuromuscular Blockade Drugs Pricing Trends (2017-2028)
1.3 World Neuromuscular Blockade Drugs Production by Region
1.3.1 World Neuromuscular Blockade Drugs Production Value by Region (2017-2028)
1.3.2 World Neuromuscular Blockade Drugs Production by Region (2017-2028)
1.3.3 World Neuromuscular Blockade Drugs Average Price by Region (2017-2028)
1.3.4 North America Neuromuscular Blockade Drugs Production (2017-2028)
1.3.5 Europe Neuromuscular Blockade Drugs Production (2017-2028)
1.3.6 China Neuromuscular Blockade Drugs Production (2017-2028)
1.3.7 Japan Neuromuscular Blockade Drugs Production (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Neuromuscular Blockade Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Neuromuscular Blockade Drugs Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Neuromuscular Blockade Drugs Demand (2017-2028)
2.2 World Neuromuscular Blockade Drugs Consumption by Region
2.2.1 World Neuromuscular Blockade Drugs Consumption by Region (2017-2022)
2.2.2 World Neuromuscular Blockade Drugs Consumption Forecast by Region (2023-2028)
2.3 United States Neuromuscular Blockade Drugs Consumption (2017-2028)
2.4 China Neuromuscular Blockade Drugs Consumption (2017-2028)
2.5 Europe Neuromuscular Blockade Drugs Consumption (2017-2028)
2.6 Japan Neuromuscular Blockade Drugs Consumption (2017-2028)
2.7 South Korea Neuromuscular Blockade Drugs Consumption (2017-2028)
2.8 ASEAN Neuromuscular Blockade Drugs Consumption (2017-2028)
2.9 India Neuromuscular Blockade Drugs Consumption (2017-2028)
3 WORLD NEUROMUSCULAR BLOCKADE DRUGS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Neuromuscular Blockade Drugs Production Value by Manufacturer (2017-2022)
3.2 World Neuromuscular Blockade Drugs Production by Manufacturer (2017-2022)
3.3 World Neuromuscular Blockade Drugs Average Price by Manufacturer (2017-2022)
3.4 Neuromuscular Blockade Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Neuromuscular Blockade Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Neuromuscular Blockade Drugs in 2021
3.5.3 Global Concentration Ratios (CR8) for Neuromuscular Blockade Drugs in 2021
3.6 Neuromuscular Blockade Drugs Market: Overall Company Footprint Analysis
3.6.1 Neuromuscular Blockade Drugs Market: Region Footprint
3.6.2 Neuromuscular Blockade Drugs Market: Company Product Type Footprint
3.6.3 Neuromuscular Blockade Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Neuromuscular Blockade Drugs Production Value Comparison
4.1.1 United States VS China: Neuromuscular Blockade Drugs Production Value Comparison (2017 & 2021 & 2028)
4.1.2 United States VS China: Neuromuscular Blockade Drugs Production Value Market Share Comparison (2017 & 2021 & 2028)
4.2 United States VS China: Neuromuscular Blockade Drugs Production Comparison
4.2.1 United States VS China: Neuromuscular Blockade Drugs Production Comparison (2017 & 2021 & 2028)
4.2.2 United States VS China: Neuromuscular Blockade Drugs Production Market Share Comparison (2017 & 2021 & 2028)
4.3 United States VS China: Neuromuscular Blockade Drugs Consumption Comparison
4.3.1 United States VS China: Neuromuscular Blockade Drugs Consumption Comparison (2017 & 2021 & 2028)
4.3.2 United States VS China: Neuromuscular Blockade Drugs Consumption Market Share Comparison (2017 & 2021 & 2028)
4.4 United States Neuromuscular Blockade Drugs Key Producers and Market Share, 2017-2022
4.4.1 Major Manufacturer of Neuromuscular Blockade Drugs in United States, Company Headquarters and Production Place (States, Country)
4.4.2 United States Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022)
4.4.3 United States Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022)
4.5 China Neuromuscular Blockade Drugs Key Producers and Market Share, 2017-2022
4.5.1 Major Manufacturer of Neuromuscular Blockade Drugs in China, Company Headquarters and Production Place (Province, Country)
4.5.2 China Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022)
4.5.3 China Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022)
4.6 Rest of World Neuromuscular Blockade Drugs Key Producers and Market Share, 2017-2022
4.6.1 Major Manufacturer of Neuromuscular Blockade Drugs in Rest of World, Company Headquarters and Production Place (State, Country)
4.6.2 Rest of World Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022)
4.6.3 Rest of World Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022)
5 MARKET ANALYSIS BY TYPE
5.1 World Neuromuscular Blockade Drugs Market Size Overview by Type: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Type
5.2.1 Depolarizing
5.2.2 Non-Depolarizing
5.3 Market Segment by Type
5.3.1 World Neuromuscular Blockade Drugs Production by Type (2017-2028)
5.3.2 World Neuromuscular Blockade Drugs Production Value by Type (2017-2028)
5.3.3 World Neuromuscular Blockade Drugs Average Price by Type (2017-2028)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Neuromuscular Blockade Drugs Market Size Overview by Application: 2017 VS 2021 VS 2028
6.2 Segment Introduction by Application
6.2.1 Hospitals
6.2.2 Specialty Clinics
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Neuromuscular Blockade Drugs Production by Application (2017-2028)
6.3.2 World Neuromuscular Blockade Drugs Production Value by Application (2017-2028)
6.3.3 World Neuromuscular Blockade Drugs Average Price by Application (2017-2028)
7 COMPANY PROFILES
7.1 F. Hoffmann-La Roche Ltd
7.1.1 F. Hoffmann-La Roche Ltd Details
7.1.2 F. Hoffmann-La Roche Ltd Major Business
7.1.3 F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Product and Services
7.1.4 F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
7.1.6 F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
7.2 Mylan N.V
7.2.1 Mylan N.V Details
7.2.2 Mylan N.V Major Business
7.2.3 Mylan N.V Neuromuscular Blockade Drugs Product and Services
7.2.4 Mylan N.V Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.2.5 Mylan N.V Recent Developments/Updates
7.2.6 Mylan N.V Competitive Strengths & Weaknesses
7.3 Teva Pharmaceutical Industries Ltd
7.3.1 Teva Pharmaceutical Industries Ltd Details
7.3.2 Teva Pharmaceutical Industries Ltd Major Business
7.3.3 Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product and Services
7.3.4 Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.3.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
7.3.6 Teva Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
7.4 Sanofi
7.4.1 Sanofi Details
7.4.2 Sanofi Major Business
7.4.3 Sanofi Neuromuscular Blockade Drugs Product and Services
7.4.4 Sanofi Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.4.5 Sanofi Recent Developments/Updates
7.4.6 Sanofi Competitive Strengths & Weaknesses
7.5 Pfizer Inc
7.5.1 Pfizer Inc Details
7.5.2 Pfizer Inc Major Business
7.5.3 Pfizer Inc Neuromuscular Blockade Drugs Product and Services
7.5.4 Pfizer Inc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.5.5 Pfizer Inc Recent Developments/Updates
7.5.6 Pfizer Inc Competitive Strengths & Weaknesses
7.6 GSK plc
7.6.1 GSK plc Details
7.6.2 GSK plc Major Business
7.6.3 GSK plc Neuromuscular Blockade Drugs Product and Services
7.6.4 GSK plc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.6.5 GSK plc Recent Developments/Updates
7.6.6 GSK plc Competitive Strengths & Weaknesses
7.7 Novartis AG
7.7.1 Novartis AG Details
7.7.2 Novartis AG Major Business
7.7.3 Novartis AG Neuromuscular Blockade Drugs Product and Services
7.7.4 Novartis AG Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.7.5 Novartis AG Recent Developments/Updates
7.7.6 Novartis AG Competitive Strengths & Weaknesses
7.8 AstraZeneca
7.8.1 AstraZeneca Details
7.8.2 AstraZeneca Major Business
7.8.3 AstraZeneca Neuromuscular Blockade Drugs Product and Services
7.8.4 AstraZeneca Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.8.5 AstraZeneca Recent Developments/Updates
7.8.6 AstraZeneca Competitive Strengths & Weaknesses
7.9 Johnson & Johnson Private Limited
7.9.1 Johnson & Johnson Private Limited Details
7.9.2 Johnson & Johnson Private Limited Major Business
7.9.3 Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Product and Services
7.9.4 Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.9.5 Johnson & Johnson Private Limited Recent Developments/Updates
7.9.6 Johnson & Johnson Private Limited Competitive Strengths & Weaknesses
7.10 Sun Pharmaceutical Industries Ltd
7.10.1 Sun Pharmaceutical Industries Ltd Details
7.10.2 Sun Pharmaceutical Industries Ltd Major Business
7.10.3 Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product and Services
7.10.4 Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.10.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
7.10.6 Sun Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
7.11 Merck & Co., Inc
7.11.1 Merck & Co., Inc Details
7.11.2 Merck & Co., Inc Major Business
7.11.3 Merck & Co., Inc Neuromuscular Blockade Drugs Product and Services
7.11.4 Merck & Co., Inc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.11.5 Merck & Co., Inc Recent Developments/Updates
7.11.6 Merck & Co., Inc Competitive Strengths & Weaknesses
7.12 Lilly
7.12.1 Lilly Details
7.12.2 Lilly Major Business
7.12.3 Lilly Neuromuscular Blockade Drugs Product and Services
7.12.4 Lilly Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.12.5 Lilly Recent Developments/Updates
7.12.6 Lilly Competitive Strengths & Weaknesses
7.13 Amgen Inc
7.13.1 Amgen Inc Details
7.13.2 Amgen Inc Major Business
7.13.3 Amgen Inc Neuromuscular Blockade Drugs Product and Services
7.13.4 Amgen Inc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.13.5 Amgen Inc Recent Developments/Updates
7.13.6 Amgen Inc Competitive Strengths & Weaknesses
7.14 Actelion Pharmaceuticals Ltd
7.14.1 Actelion Pharmaceuticals Ltd Details
7.14.2 Actelion Pharmaceuticals Ltd Major Business
7.14.3 Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product and Services
7.14.4 Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.14.5 Actelion Pharmaceuticals Ltd Recent Developments/Updates
7.14.6 Actelion Pharmaceuticals Ltd Competitive Strengths & Weaknesses
7.15 Endo International plc
7.15.1 Endo International plc Details
7.15.2 Endo International plc Major Business
7.15.3 Endo International plc Neuromuscular Blockade Drugs Product and Services
7.15.4 Endo International plc Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.15.5 Endo International plc Recent Developments/Updates
7.15.6 Endo International plc Competitive Strengths & Weaknesses
7.16 Intas Pharmaceuticals Ltd
7.16.1 Intas Pharmaceuticals Ltd Details
7.16.2 Intas Pharmaceuticals Ltd Major Business
7.16.3 Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product and Services
7.16.4 Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.16.5 Intas Pharmaceuticals Ltd Recent Developments/Updates
7.16.6 Intas Pharmaceuticals Ltd Competitive Strengths & Weaknesses
8 RAW MATERIAL AND INDUSTRY CHAIN
8.1 Raw Material of Neuromuscular Blockade Drugs and Key Manufacturers
8.2 Neuromuscular Blockade Drugs Manufacturing Costs
8.3 Neuromuscular Blockade Drugs Production Process
8.4 Neuromuscular Blockade Drugs Industrial Chain
9 DISTRIBUTION CHANNEL ANALYSIS
9.1 Distribution Channel Breakdown for Neuromuscular Blockade Drugs Shipments (%): 2017-2028
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Neuromuscular Blockade Drugs Typical Distributors
9.3 Neuromuscular Blockade Drugs Typical Customers
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
LIST OF TABLES
Table 1. World Neuromuscular Blockade Drugs Production Value by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Neuromuscular Blockade Drugs Production Value by Region (2017-2022) & (USD Million)
Table 3. World Neuromuscular Blockade Drugs Production Value by Region (2023-2028) & (USD Million)
Table 4. World Neuromuscular Blockade Drugs Production Value Market Share by Region (2017-2022)
Table 5. World Neuromuscular Blockade Drugs Production Value Market Share by Region (2023-2028)
Table 6. World Neuromuscular Blockade Drugs Production by Region (2017-2022) & (K Units)
Table 7. World Neuromuscular Blockade Drugs Production by Region (2023-2028) & (K Units)
Table 8. World Neuromuscular Blockade Drugs Production Market Share by Region (2017-2022)
Table 9. World Neuromuscular Blockade Drugs Production Market Share by Region (2023-2028)
Table 10. World Neuromuscular Blockade Drugs Average Price by Region (2017-2022) & (US$/Unit)
Table 11. World Neuromuscular Blockade Drugs Average Price by Region (2023-2028) & (US$/Unit)
Table 12. Neuromuscular Blockade Drugs Major Market Trends
Table 13. World Neuromuscular Blockade Drugs Consumption Growth Rate Forecast by Region (2017 & 2021 & 2028) & (K Units)
Table 14. World Neuromuscular Blockade Drugs Consumption by Region (2017-2022) & (K Units)
Table 15. World Neuromuscular Blockade Drugs Consumption Forecast by Region (2023-2028) & (K Units)
Table 16. World Neuromuscular Blockade Drugs Production Value by Manufacturer (2017-2022) & (USD Million)
Table 17. Production Value Market Share of Key Neuromuscular Blockade Drugs Producers in 2021
Table 18. World Neuromuscular Blockade Drugs Production by Manufacturer (2017-2022) & (K Units)
Table 19. Production Market Share of Key Neuromuscular Blockade Drugs Producers in 2021
Table 20. World Neuromuscular Blockade Drugs Average Price by Manufacturer (2017-2022) & (US$/Unit)
Table 21. Global Neuromuscular Blockade Drugs Company Evaluation Quadrant
Table 22. World Neuromuscular Blockade Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2021
Table 23. Head Office and Neuromuscular Blockade Drugs Production Site of Key Manufacturer
Table 24. Neuromuscular Blockade Drugs Market: Company Product Type Footprint
Table 25. Neuromuscular Blockade Drugs Market: Company Product Application Footprint
Table 26. Neuromuscular Blockade Drugs Competitive Factors
Table 27. Neuromuscular Blockade Drugs New Entrant and Capacity Expansion Plans
Table 28. Neuromuscular Blockade Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Neuromuscular Blockade Drugs Production Value Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 30. United States VS China Neuromuscular Blockade Drugs Production Comparison, (2017 & 2021 & 2028) & (K Units)
Table 31. United States VS China Neuromuscular Blockade Drugs Consumption Comparison, (2017 & 2021 & 2028) & (K Units)
Table 32. Major Manufacturer of Neuromuscular Blockade Drugs in United States, Company Headquarters and Production Place (States, Country)
Table 33. United States Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 34. United States Neuromuscular Blockade Drugs Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 35. United States Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 36. United States Neuromuscular Blockade Drugs Production Market Share by Domestic Manufacturer, (2017-2022)
Table 37. Major Manufacturer of Neuromuscular Blockade Drugs in China, Company Headquarters and Production Place (Province, Country)
Table 38. China Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 39. China Neuromuscular Blockade Drugs Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 40. China Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 41. China Neuromuscular Blockade Drugs Production Market Share by Domestic Manufacturer, (2017-2022)
Table 42. Major Manufacturer of Neuromuscular Blockade Drugs in Rest of World, Company Headquarters and Production Place (State, Country)
Table 43. Rest of World Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 44. Rest of World Neuromuscular Blockade Drugs Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 45. Rest of World Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 46. Rest of World Neuromuscular Blockade Drugs Production Market Share by Domestic Manufacturer, (2017-2022)
Table 47. World Neuromuscular Blockade Drugs Production Value by Type, (USD Million), 2017 & 2021 & 2028
Table 48. World Neuromuscular Blockade Drugs Production by Type (2017-2022) & (K Units)
Table 49. World Neuromuscular Blockade Drugs Production by Type (2023-2028) & (K Units)
Table 50. World Neuromuscular Blockade Drugs Production Value by Type (2017-2022) & (USD Million)
Table 51. World Neuromuscular Blockade Drugs Production Value by Type (2023-2028) & (USD Million)
Table 52. World Neuromuscular Blockade Drugs Average Price by Type (2017-2022) & (US$/Unit)
Table 53. World Neuromuscular Blockade Drugs Average Price by Type (2023-2028) & (US$/Unit)
Table 54. World Neuromuscular Blockade Drugs Production Value by Application, (USD Million), 2017 & 2021 & 2028
Table 55. World Neuromuscular Blockade Drugs Production by Application (2017-2022) & (K Units)
Table 56. World Neuromuscular Blockade Drugs Production by Application (2023-2028) & (K Units)
Table 57. World Neuromuscular Blockade Drugs Production Value by Application (2017-2022) & (USD Million)
Table 58. World Neuromuscular Blockade Drugs Production Value by Application (2023-2028) & (USD Million)
Table 59. World Neuromuscular Blockade Drugs Average Price by Application (2017-2022) & (US$/Unit)
Table 60. World Neuromuscular Blockade Drugs Average Price by Application (2023-2028) & (US$/Unit)
Table 61. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 62. F. Hoffmann-La Roche Ltd Major Business
Table 63. F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Product and Services
Table 64. F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 65. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 66. F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
Table 67. Mylan N.V Basic Information, Manufacturing Base and Competitors
Table 68. Mylan N.V Major Business
Table 69. Mylan N.V Neuromuscular Blockade Drugs Product and Services
Table 70. Mylan N.V Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 71. Mylan N.V Recent Developments/Updates
Table 72. Mylan N.V Competitive Strengths & Weaknesses
Table 73. Teva Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 74. Teva Pharmaceutical Industries Ltd Major Business
Table 75. Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product and Services
Table 76. Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 77. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
Table 78. Teva Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
Table 79. Sanofi Basic Information, Manufacturing Base and Competitors
Table 80. Sanofi Major Business
Table 81. Sanofi Neuromuscular Blockade Drugs Product and Services
Table 82. Sanofi Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 83. Sanofi Recent Developments/Updates
Table 84. Sanofi Competitive Strengths & Weaknesses
Table 85. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 86. Pfizer Inc Major Business
Table 87. Pfizer Inc Neuromuscular Blockade Drugs Product and Services
Table 88. Pfizer Inc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 89. Pfizer Inc Recent Developments/Updates
Table 90. Pfizer Inc Competitive Strengths & Weaknesses
Table 91. GSK plc Basic Information, Manufacturing Base and Competitors
Table 92. GSK plc Major Business
Table 93. GSK plc Neuromuscular Blockade Drugs Product and Services
Table 94. GSK plc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 95. GSK plc Recent Developments/Updates
Table 96. GSK plc Competitive Strengths & Weaknesses
Table 97. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 98. Novartis AG Major Business
Table 99. Novartis AG Neuromuscular Blockade Drugs Product and Services
Table 100. Novartis AG Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 101. Novartis AG Recent Developments/Updates
Table 102. Novartis AG Competitive Strengths & Weaknesses
Table 103. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 104. AstraZeneca Major Business
Table 105. AstraZeneca Neuromuscular Blockade Drugs Product and Services
Table 106. AstraZeneca Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 107. AstraZeneca Recent Developments/Updates
Table 108. AstraZeneca Competitive Strengths & Weaknesses
Table 109. Johnson & Johnson Private Limited Basic Information, Manufacturing Base and Competitors
Table 110. Johnson & Johnson Private Limited Major Business
Table 111. Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Product and Services
Table 112. Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 113. Johnson & Johnson Private Limited Recent Developments/Updates
Table 114. Johnson & Johnson Private Limited Competitive Strengths & Weaknesses
Table 115. Sun Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 116. Sun Pharmaceutical Industries Ltd Major Business
Table 117. Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product and Services
Table 118. Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 119. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
Table 120. Sun Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
Table 121. Merck & Co., Inc Basic Information, Manufacturing Base and Competitors
Table 122. Merck & Co., Inc Major Business
Table 123. Merck & Co., Inc Neuromuscular Blockade Drugs Product and Services
Table 124. Merck & Co., Inc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 125. Merck & Co., Inc Recent Developments/Updates
Table 126. Merck & Co., Inc Competitive Strengths & Weaknesses
Table 127. Lilly Basic Information, Manufacturing Base and Competitors
Table 128. Lilly Major Business
Table 129. Lilly Neuromuscular Blockade Drugs Product and Services
Table 130. Lilly Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 131. Lilly Recent Developments/Updates
Table 132. Lilly Competitive Strengths & Weaknesses
Table 133. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 134. Amgen Inc Major Business
Table 135. Amgen Inc Neuromuscular Blockade Drugs Product and Services
Table 136. Amgen Inc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 137. Amgen Inc Recent Developments/Updates
Table 138. Amgen Inc Competitive Strengths & Weaknesses
Table 139. Actelion Pharmaceuticals Ltd Basic Information, Manufacturing Base and Competitors
Table 140. Actelion Pharmaceuticals Ltd Major Business
Table 141. Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product and Services
Table 142. Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 143. Actelion Pharmaceuticals Ltd Recent Developments/Updates
Table 144. Actelion Pharmaceuticals Ltd Competitive Strengths & Weaknesses
Table 145. Endo International plc Basic Information, Manufacturing Base and Competitors
Table 146. Endo International plc Major Business
Table 147. Endo International plc Neuromuscular Blockade Drugs Product and Services
Table 148. Endo International plc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 149. Endo International plc Recent Developments/Updates
Table 150. Intas Pharmaceuticals Ltd Basic Information, Manufacturing Base and Competitors
Table 151. Intas Pharmaceuticals Ltd Major Business
Table 152. Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product and Services
Table 153. Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 154. Neuromuscular Blockade Drugs Raw Material
Table 155. Key Manufacturers of Neuromuscular Blockade Drugs Raw Materials
Table 156. Neuromuscular Blockade Drugs Typical Distributors
Table 157. Neuromuscular Blockade Drugs Typical Customers
Table 1. World Neuromuscular Blockade Drugs Production Value by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Neuromuscular Blockade Drugs Production Value by Region (2017-2022) & (USD Million)
Table 3. World Neuromuscular Blockade Drugs Production Value by Region (2023-2028) & (USD Million)
Table 4. World Neuromuscular Blockade Drugs Production Value Market Share by Region (2017-2022)
Table 5. World Neuromuscular Blockade Drugs Production Value Market Share by Region (2023-2028)
Table 6. World Neuromuscular Blockade Drugs Production by Region (2017-2022) & (K Units)
Table 7. World Neuromuscular Blockade Drugs Production by Region (2023-2028) & (K Units)
Table 8. World Neuromuscular Blockade Drugs Production Market Share by Region (2017-2022)
Table 9. World Neuromuscular Blockade Drugs Production Market Share by Region (2023-2028)
Table 10. World Neuromuscular Blockade Drugs Average Price by Region (2017-2022) & (US$/Unit)
Table 11. World Neuromuscular Blockade Drugs Average Price by Region (2023-2028) & (US$/Unit)
Table 12. Neuromuscular Blockade Drugs Major Market Trends
Table 13. World Neuromuscular Blockade Drugs Consumption Growth Rate Forecast by Region (2017 & 2021 & 2028) & (K Units)
Table 14. World Neuromuscular Blockade Drugs Consumption by Region (2017-2022) & (K Units)
Table 15. World Neuromuscular Blockade Drugs Consumption Forecast by Region (2023-2028) & (K Units)
Table 16. World Neuromuscular Blockade Drugs Production Value by Manufacturer (2017-2022) & (USD Million)
Table 17. Production Value Market Share of Key Neuromuscular Blockade Drugs Producers in 2021
Table 18. World Neuromuscular Blockade Drugs Production by Manufacturer (2017-2022) & (K Units)
Table 19. Production Market Share of Key Neuromuscular Blockade Drugs Producers in 2021
Table 20. World Neuromuscular Blockade Drugs Average Price by Manufacturer (2017-2022) & (US$/Unit)
Table 21. Global Neuromuscular Blockade Drugs Company Evaluation Quadrant
Table 22. World Neuromuscular Blockade Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2021
Table 23. Head Office and Neuromuscular Blockade Drugs Production Site of Key Manufacturer
Table 24. Neuromuscular Blockade Drugs Market: Company Product Type Footprint
Table 25. Neuromuscular Blockade Drugs Market: Company Product Application Footprint
Table 26. Neuromuscular Blockade Drugs Competitive Factors
Table 27. Neuromuscular Blockade Drugs New Entrant and Capacity Expansion Plans
Table 28. Neuromuscular Blockade Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Neuromuscular Blockade Drugs Production Value Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 30. United States VS China Neuromuscular Blockade Drugs Production Comparison, (2017 & 2021 & 2028) & (K Units)
Table 31. United States VS China Neuromuscular Blockade Drugs Consumption Comparison, (2017 & 2021 & 2028) & (K Units)
Table 32. Major Manufacturer of Neuromuscular Blockade Drugs in United States, Company Headquarters and Production Place (States, Country)
Table 33. United States Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 34. United States Neuromuscular Blockade Drugs Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 35. United States Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 36. United States Neuromuscular Blockade Drugs Production Market Share by Domestic Manufacturer, (2017-2022)
Table 37. Major Manufacturer of Neuromuscular Blockade Drugs in China, Company Headquarters and Production Place (Province, Country)
Table 38. China Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 39. China Neuromuscular Blockade Drugs Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 40. China Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 41. China Neuromuscular Blockade Drugs Production Market Share by Domestic Manufacturer, (2017-2022)
Table 42. Major Manufacturer of Neuromuscular Blockade Drugs in Rest of World, Company Headquarters and Production Place (State, Country)
Table 43. Rest of World Neuromuscular Blockade Drugs Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 44. Rest of World Neuromuscular Blockade Drugs Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 45. Rest of World Neuromuscular Blockade Drugs Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 46. Rest of World Neuromuscular Blockade Drugs Production Market Share by Domestic Manufacturer, (2017-2022)
Table 47. World Neuromuscular Blockade Drugs Production Value by Type, (USD Million), 2017 & 2021 & 2028
Table 48. World Neuromuscular Blockade Drugs Production by Type (2017-2022) & (K Units)
Table 49. World Neuromuscular Blockade Drugs Production by Type (2023-2028) & (K Units)
Table 50. World Neuromuscular Blockade Drugs Production Value by Type (2017-2022) & (USD Million)
Table 51. World Neuromuscular Blockade Drugs Production Value by Type (2023-2028) & (USD Million)
Table 52. World Neuromuscular Blockade Drugs Average Price by Type (2017-2022) & (US$/Unit)
Table 53. World Neuromuscular Blockade Drugs Average Price by Type (2023-2028) & (US$/Unit)
Table 54. World Neuromuscular Blockade Drugs Production Value by Application, (USD Million), 2017 & 2021 & 2028
Table 55. World Neuromuscular Blockade Drugs Production by Application (2017-2022) & (K Units)
Table 56. World Neuromuscular Blockade Drugs Production by Application (2023-2028) & (K Units)
Table 57. World Neuromuscular Blockade Drugs Production Value by Application (2017-2022) & (USD Million)
Table 58. World Neuromuscular Blockade Drugs Production Value by Application (2023-2028) & (USD Million)
Table 59. World Neuromuscular Blockade Drugs Average Price by Application (2017-2022) & (US$/Unit)
Table 60. World Neuromuscular Blockade Drugs Average Price by Application (2023-2028) & (US$/Unit)
Table 61. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 62. F. Hoffmann-La Roche Ltd Major Business
Table 63. F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Product and Services
Table 64. F. Hoffmann-La Roche Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 65. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 66. F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
Table 67. Mylan N.V Basic Information, Manufacturing Base and Competitors
Table 68. Mylan N.V Major Business
Table 69. Mylan N.V Neuromuscular Blockade Drugs Product and Services
Table 70. Mylan N.V Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 71. Mylan N.V Recent Developments/Updates
Table 72. Mylan N.V Competitive Strengths & Weaknesses
Table 73. Teva Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 74. Teva Pharmaceutical Industries Ltd Major Business
Table 75. Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product and Services
Table 76. Teva Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 77. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
Table 78. Teva Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
Table 79. Sanofi Basic Information, Manufacturing Base and Competitors
Table 80. Sanofi Major Business
Table 81. Sanofi Neuromuscular Blockade Drugs Product and Services
Table 82. Sanofi Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 83. Sanofi Recent Developments/Updates
Table 84. Sanofi Competitive Strengths & Weaknesses
Table 85. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 86. Pfizer Inc Major Business
Table 87. Pfizer Inc Neuromuscular Blockade Drugs Product and Services
Table 88. Pfizer Inc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 89. Pfizer Inc Recent Developments/Updates
Table 90. Pfizer Inc Competitive Strengths & Weaknesses
Table 91. GSK plc Basic Information, Manufacturing Base and Competitors
Table 92. GSK plc Major Business
Table 93. GSK plc Neuromuscular Blockade Drugs Product and Services
Table 94. GSK plc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 95. GSK plc Recent Developments/Updates
Table 96. GSK plc Competitive Strengths & Weaknesses
Table 97. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 98. Novartis AG Major Business
Table 99. Novartis AG Neuromuscular Blockade Drugs Product and Services
Table 100. Novartis AG Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 101. Novartis AG Recent Developments/Updates
Table 102. Novartis AG Competitive Strengths & Weaknesses
Table 103. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 104. AstraZeneca Major Business
Table 105. AstraZeneca Neuromuscular Blockade Drugs Product and Services
Table 106. AstraZeneca Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 107. AstraZeneca Recent Developments/Updates
Table 108. AstraZeneca Competitive Strengths & Weaknesses
Table 109. Johnson & Johnson Private Limited Basic Information, Manufacturing Base and Competitors
Table 110. Johnson & Johnson Private Limited Major Business
Table 111. Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Product and Services
Table 112. Johnson & Johnson Private Limited Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 113. Johnson & Johnson Private Limited Recent Developments/Updates
Table 114. Johnson & Johnson Private Limited Competitive Strengths & Weaknesses
Table 115. Sun Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 116. Sun Pharmaceutical Industries Ltd Major Business
Table 117. Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Product and Services
Table 118. Sun Pharmaceutical Industries Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 119. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
Table 120. Sun Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
Table 121. Merck & Co., Inc Basic Information, Manufacturing Base and Competitors
Table 122. Merck & Co., Inc Major Business
Table 123. Merck & Co., Inc Neuromuscular Blockade Drugs Product and Services
Table 124. Merck & Co., Inc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 125. Merck & Co., Inc Recent Developments/Updates
Table 126. Merck & Co., Inc Competitive Strengths & Weaknesses
Table 127. Lilly Basic Information, Manufacturing Base and Competitors
Table 128. Lilly Major Business
Table 129. Lilly Neuromuscular Blockade Drugs Product and Services
Table 130. Lilly Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 131. Lilly Recent Developments/Updates
Table 132. Lilly Competitive Strengths & Weaknesses
Table 133. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 134. Amgen Inc Major Business
Table 135. Amgen Inc Neuromuscular Blockade Drugs Product and Services
Table 136. Amgen Inc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 137. Amgen Inc Recent Developments/Updates
Table 138. Amgen Inc Competitive Strengths & Weaknesses
Table 139. Actelion Pharmaceuticals Ltd Basic Information, Manufacturing Base and Competitors
Table 140. Actelion Pharmaceuticals Ltd Major Business
Table 141. Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product and Services
Table 142. Actelion Pharmaceuticals Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 143. Actelion Pharmaceuticals Ltd Recent Developments/Updates
Table 144. Actelion Pharmaceuticals Ltd Competitive Strengths & Weaknesses
Table 145. Endo International plc Basic Information, Manufacturing Base and Competitors
Table 146. Endo International plc Major Business
Table 147. Endo International plc Neuromuscular Blockade Drugs Product and Services
Table 148. Endo International plc Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 149. Endo International plc Recent Developments/Updates
Table 150. Intas Pharmaceuticals Ltd Basic Information, Manufacturing Base and Competitors
Table 151. Intas Pharmaceuticals Ltd Major Business
Table 152. Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Product and Services
Table 153. Intas Pharmaceuticals Ltd Neuromuscular Blockade Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 154. Neuromuscular Blockade Drugs Raw Material
Table 155. Key Manufacturers of Neuromuscular Blockade Drugs Raw Materials
Table 156. Neuromuscular Blockade Drugs Typical Distributors
Table 157. Neuromuscular Blockade Drugs Typical Customers
LIST OF FIGURES
Figure 1. Neuromuscular Blockade Drugs Picture
Figure 2. World Neuromuscular Blockade Drugs Production Value: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Neuromuscular Blockade Drugs Production Value and Forecast (2017-2028) & (USD Million)
Figure 4. World Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 5. World Neuromuscular Blockade Drugs Average Price (2017-2028) & (US$/Unit)
Figure 6. World Neuromuscular Blockade Drugs Production Value Market Share by Region (2017-2028)
Figure 7. World Neuromuscular Blockade Drugs Production Market Share by Region (2017-2028)
Figure 8. North America Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 9. Europe Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 10. China Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 11. Japan Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 12. Neuromuscular Blockade Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Neuromuscular Blockade Drugs Demand (2017-2028) & (K Units)
Figure 15. World Neuromuscular Blockade Drugs Consumption Market Share by Region (2017-2028)
Figure 16. United States Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 17. China Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 18. Europe Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 19. Japan Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 20. South Korea Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 21. ASEAN Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 22. India Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 23. Producer Shipments of Neuromuscular Blockade Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2021
Figure 24. Global Four-firm Concentration Ratios (CR4) for Neuromuscular Blockade Drugs Markets in 2021
Figure 25. Global Four-firm Concentration Ratios (CR8) for Neuromuscular Blockade Drugs Markets in 2021
Figure 26. United States VS China: Neuromuscular Blockade Drugs Production Value Market Share Comparison (2017 & 2021 & 2028)
Figure 27. United States VS China: Neuromuscular Blockade Drugs Production Market Share Comparison (2017 & 2021 & 2028)
Figure 28. United States VS China: Neuromuscular Blockade Drugs Consumption Market Share Comparison (2017 & 2021 & 2028)
Figure 29. Key Producers and Market Share of Neuromuscular Blockade Drugs in United States
Figure 30. Key Producers and Market Share of Neuromuscular Blockade Drugs in China
Figure 31. Key Producers and Market Share of Neuromuscular Blockade Drugs in Rest of World
Figure 32. World Neuromuscular Blockade Drugs Production Value by Type, (USD Million), 2017 & 2021 & 2028
Figure 33. World Neuromuscular Blockade Drugs Production Value Market Share by Type in 2021
Figure 34. Depolarizing
Figure 35. Non-Depolarizing
Figure 36. World Neuromuscular Blockade Drugs Production Market Share by Type (2017-2028)
Figure 37. World Neuromuscular Blockade Drugs Production Value Market Share by Type (2017-2028)
Figure 38. World Neuromuscular Blockade Drugs Average Price by Type (2017-2028) & (US$/Unit)
Figure 39. World Neuromuscular Blockade Drugs Production Value by Application, (USD Million), 2017 & 2021 & 2028
Figure 40. World Neuromuscular Blockade Drugs Production Value Market Share by Application in 2021
Figure 41. Hospitals
Figure 42. Specialty Clinics
Figure 43. Other
Figure 44. World Neuromuscular Blockade Drugs Production Market Share by Application (2017-2028)
Figure 45. World Neuromuscular Blockade Drugs Production Value Market Share by Application (2017-2028)
Figure 46. World Neuromuscular Blockade Drugs Average Price by Application (2017-2028) & (US$/Unit)
Figure 47. Manufacturing Cost Structure Analysis of Neuromuscular Blockade Drugs in 2021
Figure 48. Manufacturing Process Analysis of Neuromuscular Blockade Drugs
Figure 49. Neuromuscular Blockade Drugs Industrial Chain
Figure 50. Distribution Channel Breakdown for Neuromuscular Blockade Drugs Shipments (%): 2017-2028
Figure 51. Direct Channel Pros & Cons
Figure 52. Indirect Channel Pros & Cons
Figure 53. Methodology
Figure 54. Research Process and Data Source
Figure 1. Neuromuscular Blockade Drugs Picture
Figure 2. World Neuromuscular Blockade Drugs Production Value: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Neuromuscular Blockade Drugs Production Value and Forecast (2017-2028) & (USD Million)
Figure 4. World Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 5. World Neuromuscular Blockade Drugs Average Price (2017-2028) & (US$/Unit)
Figure 6. World Neuromuscular Blockade Drugs Production Value Market Share by Region (2017-2028)
Figure 7. World Neuromuscular Blockade Drugs Production Market Share by Region (2017-2028)
Figure 8. North America Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 9. Europe Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 10. China Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 11. Japan Neuromuscular Blockade Drugs Production (2017-2028) & (K Units)
Figure 12. Neuromuscular Blockade Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Neuromuscular Blockade Drugs Demand (2017-2028) & (K Units)
Figure 15. World Neuromuscular Blockade Drugs Consumption Market Share by Region (2017-2028)
Figure 16. United States Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 17. China Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 18. Europe Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 19. Japan Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 20. South Korea Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 21. ASEAN Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 22. India Neuromuscular Blockade Drugs Consumption (2017-2028) & (K Units)
Figure 23. Producer Shipments of Neuromuscular Blockade Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2021
Figure 24. Global Four-firm Concentration Ratios (CR4) for Neuromuscular Blockade Drugs Markets in 2021
Figure 25. Global Four-firm Concentration Ratios (CR8) for Neuromuscular Blockade Drugs Markets in 2021
Figure 26. United States VS China: Neuromuscular Blockade Drugs Production Value Market Share Comparison (2017 & 2021 & 2028)
Figure 27. United States VS China: Neuromuscular Blockade Drugs Production Market Share Comparison (2017 & 2021 & 2028)
Figure 28. United States VS China: Neuromuscular Blockade Drugs Consumption Market Share Comparison (2017 & 2021 & 2028)
Figure 29. Key Producers and Market Share of Neuromuscular Blockade Drugs in United States
Figure 30. Key Producers and Market Share of Neuromuscular Blockade Drugs in China
Figure 31. Key Producers and Market Share of Neuromuscular Blockade Drugs in Rest of World
Figure 32. World Neuromuscular Blockade Drugs Production Value by Type, (USD Million), 2017 & 2021 & 2028
Figure 33. World Neuromuscular Blockade Drugs Production Value Market Share by Type in 2021
Figure 34. Depolarizing
Figure 35. Non-Depolarizing
Figure 36. World Neuromuscular Blockade Drugs Production Market Share by Type (2017-2028)
Figure 37. World Neuromuscular Blockade Drugs Production Value Market Share by Type (2017-2028)
Figure 38. World Neuromuscular Blockade Drugs Average Price by Type (2017-2028) & (US$/Unit)
Figure 39. World Neuromuscular Blockade Drugs Production Value by Application, (USD Million), 2017 & 2021 & 2028
Figure 40. World Neuromuscular Blockade Drugs Production Value Market Share by Application in 2021
Figure 41. Hospitals
Figure 42. Specialty Clinics
Figure 43. Other
Figure 44. World Neuromuscular Blockade Drugs Production Market Share by Application (2017-2028)
Figure 45. World Neuromuscular Blockade Drugs Production Value Market Share by Application (2017-2028)
Figure 46. World Neuromuscular Blockade Drugs Average Price by Application (2017-2028) & (US$/Unit)
Figure 47. Manufacturing Cost Structure Analysis of Neuromuscular Blockade Drugs in 2021
Figure 48. Manufacturing Process Analysis of Neuromuscular Blockade Drugs
Figure 49. Neuromuscular Blockade Drugs Industrial Chain
Figure 50. Distribution Channel Breakdown for Neuromuscular Blockade Drugs Shipments (%): 2017-2028
Figure 51. Direct Channel Pros & Cons
Figure 52. Indirect Channel Pros & Cons
Figure 53. Methodology
Figure 54. Research Process and Data Source
